Profile data is unavailable for this security.
About the company
AVE Science & Technology Co Ltd is a China-based company principally engaged in the research and development, production, sales and service of medical clinical laboratory analysis instruments and supporting in vitro diagnostic reagents and medical consumables. The Company’s main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables and other products. The Company's products are mainly used in inspection departments of various medical and health institutions. The Company distributes its products both in the domestic market and to overseas markets.
- Revenue in CNY (TTM)206.22m
- Net income in CNY24.46m
- Incorporated2000
- Employees492.00
- LocationAVE Science & Technology Co LtdAVE Medical Technology Park, No. 26Fuling Road, Xueshi Neighborhood, YueluCHANGSHA 410208ChinaCHN
- Phone+86 73 189715453
- Fax+86 73 188907046
- Websitehttp://www.c-ave.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hangzhou Tianmushan Phrmtcl ntrprs C Ltd | 137.86m | -38.94m | 994.93m | 380.00 | -- | 36.29 | -- | 7.22 | -0.3198 | -0.3198 | 1.13 | 0.2251 | 0.4619 | 2.30 | 3.90 | 362,781.80 | -13.21 | -6.93 | -54.44 | -18.92 | 21.16 | 33.95 | -28.59 | -16.42 | 0.5282 | -4.37 | 0.6609 | -- | 11.82 | -19.42 | 43.35 | -- | -24.89 | -- |
| Dali Pharmaceutical Co Ltd | 65.70m | -22.85m | 1.09bn | 272.00 | -- | 2.91 | -- | 16.62 | -0.104 | -0.104 | 0.2991 | 1.71 | 0.1381 | 1.15 | 15.89 | 241,555.10 | -4.80 | -2.31 | -5.61 | -2.77 | 22.16 | 65.39 | -34.78 | -7.00 | 3.11 | -- | 0.0593 | -- | -34.06 | -26.30 | -13.16 | -- | 16.34 | -- |
| AVE Science & Technology Co Ltd | 206.22m | 24.46m | 1.17bn | 492.00 | 47.65 | 2.36 | -- | 5.65 | 0.3597 | 0.3597 | 3.03 | 7.28 | 0.3795 | 2.04 | 33.65 | 419,148.40 | 4.50 | 7.21 | 4.92 | 8.18 | 55.69 | 58.93 | 11.86 | 15.48 | 5.60 | -- | 0.00 | 22.46 | 1.79 | 5.88 | 19.81 | -4.62 | -23.68 | -- |
| Shanghai Rendu Biotechnology Co Ltd | 180.85m | -8.77m | 1.35bn | 528.00 | -- | 1.42 | -- | 7.49 | -0.2192 | -0.2192 | 4.52 | 23.78 | 0.1695 | 1.82 | 1.99 | 342,521.40 | -0.8215 | -- | -0.8869 | -- | 70.19 | -- | -4.85 | -- | 13.78 | -- | 0.008 | -- | 3.95 | -- | -63.89 | -- | -- | -- |
| Shaanxi Kanghui Pharmaceutical Co Ltd | 588.60m | -70.10m | 1.44bn | 828.00 | -- | 1.46 | -- | 2.44 | -0.7018 | -0.7018 | 5.89 | 9.84 | 0.289 | 2.23 | 3.02 | 710,868.00 | -4.51 | 1.41 | -6.35 | 1.71 | 30.41 | 45.74 | -15.60 | 4.48 | 0.8839 | -2.79 | 0.4034 | 32.34 | 11.01 | 6.01 | -272.84 | -- | 107.49 | -- |
| Shanghai Rightongene Biotechnlgy Co Ltd | 265.52m | 7.17m | 1.44bn | 501.00 | 194.10 | 1.55 | -- | 5.44 | 0.1332 | 0.1332 | 4.75 | 16.67 | 0.2540 | 1.09 | 1.40 | 529,970.30 | -0.0901 | 4.16 | -0.098 | 4.49 | 75.02 | 70.45 | -0.3548 | 11.62 | 10.43 | -- | 0.0284 | 5.90 | -39.14 | 2.84 | -80.41 | -11.46 | 19.65 | -- |
| Shanghai Serum Bio-Technology Co Ltd | 192.49m | 37.23m | 1.60bn | 321.00 | 42.96 | 1.47 | -- | 8.31 | 0.3441 | 0.3441 | 1.78 | 10.05 | 0.1689 | 0.9282 | 6.82 | 599,656.40 | 3.27 | 10.43 | 3.32 | 10.84 | 75.08 | 80.54 | 19.34 | 32.57 | 50.03 | -- | 0.0119 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Shanghai Jiaoda Onlly Co Ltd | 280.54m | -39.86m | 1.72bn | 935.00 | -- | 5.90 | -- | 6.13 | -0.0514 | -0.0514 | 0.362 | 0.3761 | 0.3475 | 5.15 | 4.63 | 300,042.20 | -4.64 | -7.62 | -7.62 | -10.70 | 18.03 | 40.06 | -13.36 | -27.01 | 0.6301 | -1.40 | 0.3455 | -- | -21.43 | 2.65 | 92.96 | -- | -34.81 | -- |
| Guangzhou LBP Medicine Scnc&Tech Co Ltd | 508.01m | 40.23m | 1.73bn | 907.00 | 43.15 | 1.36 | -- | 3.41 | 0.4292 | 0.4292 | 5.32 | 13.61 | 0.3719 | 2.12 | 2.15 | 560,104.20 | 1.83 | 5.10 | 1.91 | 5.55 | 67.83 | 75.15 | 4.91 | 12.97 | 6.70 | -- | 0.0068 | 24.42 | -1.99 | 10.18 | -6.18 | -8.21 | -2.98 | -- |
Data as of May 17 2024. Currency figures normalised to AVE Science & Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
8.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2023 | 587.04k | 4.24% |
| Gfund Management Co., Ltd.as of 31 Dec 2023 | 394.41k | 2.85% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 49.63k | 0.36% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2023 | 29.35k | 0.21% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 23.50k | 0.17% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 21.20k | 0.15% |
| Broad Fund Management Co. Ltd.as of 31 Dec 2023 | 14.70k | 0.11% |
| Nuode Asset Management Co., Ltd.as of 31 Dec 2023 | 7.95k | 0.06% |
| Fortune & Royal Asset Management Co., Ltd.as of 31 Dec 2023 | 5.80k | 0.04% |
| CCB Principal Asset Management Co., Ltd.as of 31 Dec 2023 | 5.40k | 0.04% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
